Biolump
Content |
Owners
CJSC Biocom in 2013 became the first Russian pharmaceutical manufacturer to receive the status of an approved manufacturer of medicines of the World Health Organization. The plant produces 22 MNS: 270 million tablets, 10 million capsules, 12 million packages of medicines per year, mainly antibacterial generic drugs and drugs for the treatment of CNS and cardiovascular diseases. In addition to the integrated production of medicines, the plant is engaged in packaging, labeling, and quality control of medicines at any stage of production according to the international quality standard GMP of the European Union.
CJSC Biocom is a full-cycle production specializing in the production of high-quality generics. Among them is the antimalarial drug Hydroxychloroquine developed by Biocom CJSC (included in the list of VHLP), in May 2017 it was included in the State Register of Medicines.
History
2021: Completion of investment project to modernize the plant for 1 billion rubles
On August 6, 2021, the pharmaceutical company Binnopharm Group, combining the specialized assets of AFK Sistema, informed Zdrav.Expert about the completion of an investment project to modernize the Biocom plant in Stavropol. About 1 billion rubles were invested in the development of the enterprise.
Источник фото: RBC
 | We equipped Biocom equipment the European with production, including the introduction of granulation technology not previously used at the plant. They also created a technological laboratory where samples are developed for clinical research and the process of making drugs is being improved. Modernization made it possible to bring the enterprise to a higher technological level and increase efficiency indicators. This is the Binnopharm Group approach to the development of production sites, said CEO of Binnopharm Group Rustem Muratov.
|  |
The introduction of technologies made it possible to include in the product portfolio preparations that are made with their use - in parallel with the modernization of the plant, the company conducted R&D and registered MNS (abbr. From the international generic name). As a result, the portfolio of the production site increased by a third - to 42 items, 16 of which are included in the list of housing and communal services. These are drugs for the treatment of diseases of the nervous system, the gastrointestinal tract, tuberculosis, the prevention of influenza and SARS.
Biocom specializes in the production of solid dosage forms. As of August 2021, the site meets all the requirements of the GMP standards (abbr. From Good Manufacturing Practice, or "Proper Production Practice") and has passed the first stage on the way to certification according to the EAEU Rules - the quality director and head of the quality assurance department "Biocom" are certified as Authorized Persons according to the EAEU requirements.
2020: Inclusion in Binopharm Group Holding
On October 30, 2020, Synthesis informed Zdrav.Expert that the pharmaceutical holding combining the portfolio companies of AFK Sistema - Alium JSC (includes Binnofarm JSC) and Synthesis OJSC (includes Biocom CJSC) announced strategic development directions. The holding will operate under the brand name Binnopharm Group. More details here.
2019
AFK Sistema closed the acquisition of Synthesis and Biocom
On August 8, 2019, Marathon Group and AFK Sistema closed a deal to acquire the pharmaceutical companies Synthesis and Biocom. This was announced on August 8, 2019 by the Marathon Group.
The parties announce the completion of the acquisition of Sistema with the financial partner of the 46.5% shares of the Kurgan medical Company of Drugs and Products Synthesis OJSC (hereinafter - Sinocom OJSC) and the 75.1% of shares of Biocom CJSC through the holding company Sinocom Investments Limited (hereinafter - Sinocom) from the investment company Marathon Group for 11.8 billion. rubles
The share in the authorized capital of Synthesis OJSC in the amount of 46.5% was acquired for 8.2 billion rubles by Sinocom, financed by Sistema AFK together with a financial partner. At the next stage, as part of the integration of the businesses of the acquired companies, Synthesis OJSC acquired a stake in Biocom CJSC in the amount of 75.1% for 3.6 billion rubles from Sinocom. Purchase of shares of CJSC "Biocom" was financed at the expense of own and credit funds of OJSC "Synthesis." Companies whose portfolios are complementary in the type of products sold, have long been cooperating in the field of sales and have a single management. Consolidation of these assets on the basis of OJSC "Synthesis" will allow to realize existing synergies and will contribute to further growth of their shareholder value.
Sinocom intends to send a public offer (mandatory offer) to the minority shareholders of OJSC Synthesis on the acquisition of ordinary registered shares of this enterprise owned by them.
AFK Sistema and the financial partner entered into an agreement to acquire the share of the financial partner in Sinocom by the corporation no later than three years after the completion of the transaction.
OJSC Synthesis and CJSC Biocom, together with Alium, a combined pharmaceutical company created by AFK Sistema on the basis of JSC FP Obolenskoye and JSC Binnofarm, can form a large player with the potential to enter the top 3 Russian pharmaceutical companies in the commercial segment. The joint product portfolio of Synthesis OJSC, Biocom CJSC and Alium will include more than 500 items, and production facilities are represented by six pharmaceutical production complexes in Moscow and the Moscow Region, Kurgan and Stavropol.
AFK Sistema will acquire Synthesis and Biocom from Marathon Group
AFK Sistema, a public Russian diversified holding company, and the investment company Marathon Group on June 7, 2019 announced the signing of binding documentation on the acquisition of shares in two pharmaceutical companies - the Kurgan Society of Medical Drugs and Products Synthesis and Biocom. The closing of the transaction is expected within three months, after receiving the approval of the FAS and fulfilling other mandatory conditions. The price of the transaction is not disclosed, but, as specified, depends on a number of conditions agreed by the parties.
As noted, upon completion of the deal "Synthesis" and "Biocom" at the next stage of integration may become part of Alium, a combined pharmaceutical company created on the basis of the pharmaceutical enterprise "Obolenskoye" and "Binnofarma." It is assumed that after the integration of Synthesis and Biocom, the combined company Alium will enter the top 3 Russian pharmaceutical companies in the commercial segment. Alium's product portfolio will include more than 500 items, and production facilities are represented by six pharmaceutical production complexes in Moscow and the Moscow Region, Kurgan and Stavropol.
| | The possibility of acquiring the companies "Synthesis" and "Biocom" is investment attractive for AFK Sistema. These companies have stable market positions. In addition, we see excellent opportunities for implementing synergistic effects when combining them with the Obolenskoye and Binnopharm pharmaceutical enterprises. The deal will create one of the largest pharmaceutical companies in Russia with a diversified product portfolio, experienced management, and powerful production and research potential. It will also help optimize marketing and promotion costs, reduce administrative costs, increase geographical coverage of sales, which together will ensure a further increase in the cost of the share of AFK Sistema in this business, "commented the president of AFK Sistema Andrei Dubovskov. | |
2017: Marathon Group repurchase of 5% stake from minority shareholder
Marathon Group on December 5, 2017 announced the closure of the transaction to acquire a 5% stake in ordinary registered shares of the Stavropol pharmaceutical plant Biocom from a minority shareholder. The amount of the transaction is not disclosed, however, it is indicated that the payment was made in cash. As a result, the consolidated stake in Biocom CJSC, controlled by the Marathon Group, reached 80.1%, the remaining shares belong to the management of the enterprise.
| | Biocom is an excellent asset, a modern enterprise that is completely within the framework of Marathon Pharma's strategic plans, so we were pleased with the opportunity to increase its stake in its share capital, "commented Marathon Group President Alexander Vinokurov. - A minority stake owned by the management of the enterprise is the key to achieving our common goals for the further development of the asset. | |
In the coming years, the company plans to more than double the plant's capacity (up to 26 million packages per year) and release five more drugs. Including the antimalarial drug Hydroxychloroquine developed by Biok, which was included in the State Register of Medicines in May 2017. It is planned that by the end of 2017 the drug will appear on the market.
Hydroxychloroquine is included in the list of vital and essential drugs (VHLP). According to December 2017, Biocom produces only 15 MNNs (international generic names) from the list of housing and communal services, and in 2017 a total of 2.2 million packages of such drugs were produced.
1991: Foundation of the company
CJSC Biocom was founded in 1991 as a manufacturer of immunobiological drugs.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |